Brief: Sino Biopharmaceutical Approval For Marketing Of Kras G12c Inhibitor Garsorasib Tablet From Nmpa
11/11/2024 01:29
Nov 11 (Reuters) - Sino Biopharmaceutical 1177.HK :
* APPROVAL FOR MARKETING OF KRAS G12C INHIBITOR GARSORASIB
TABLET
FROM NMPA
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit